{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:30:53Z","timestamp":1794360653183,"version":"4.9.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41434-024-00494-6","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:03:57Z","timestamp":1729699437000},"page":"541-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["AAV gene therapy for Duchenne Muscular Dystrophy: lessons learned from a phase 3 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-6692","authenticated-orcid":false,"given":"Giovanni","family":"Baranello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"494_CR1","unstructured":"FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy. 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy."},{"key":"494_CR2","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1212\/WNL.0000000000203455","volume":"100","author":"F Muntoni","year":"2023","unstructured":"Muntoni F, Mercuri E, Schara Schmidt U, Komaki H, Richardson J, Singh T, et al. EMBARK, a Phase 3 Trial Evaluating Safety and Efficacy of Delandistrogene Moxeparvovec (SRP- 9001) in Duchenne Muscular Dystrophy (DMD): Study Design and Baseline Characteristics. Neurology. 2023;100:3691.","journal-title":"Neurology"},{"key":"494_CR3","doi-asserted-by":"publisher","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03304-z. Online ahead of print.","DOI":"10.1038\/s41591-024-03304-z"},{"key":"494_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pri.520","volume":"17","author":"E Scott","year":"2012","unstructured":"Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int. 2012;17:101\u20139.","journal-title":"Physiother Res Int"},{"key":"494_CR5","doi-asserted-by":"publisher","first-page":"e0283669","DOI":"10.1371\/journal.pone.0283669","volume":"18","author":"V Ayyar Gupta","year":"2023","unstructured":"Ayyar Gupta V, Pitchforth JM, Domingos J, Ridout D, Iodice M, Rye C, et al. iMDEX Consortium and the U.K. NorthStar Clinical Network. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS One. 2023;18:e0283669.","journal-title":"PLoS One"},{"key":"494_CR6","doi-asserted-by":"publisher","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","volume":"14","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Domingos J, Manzur AY, Mayhew A, Guglieri M, UK NorthStar Network. et al. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. PLoS One. 2019;14:e0221097. https:\/\/doi.org\/10.1371\/journal.pone.0221097.","journal-title":"PLoS One"},{"key":"494_CR7","doi-asserted-by":"publisher","first-page":"e0271681","DOI":"10.1371\/journal.pone.0271681","volume":"17","author":"G Coratti","year":"2022","unstructured":"Coratti G, Lenkowicz J, Norcia G, Lucibello S, Ferraroli E, d\u2019Amico A, et al. Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy. PLoS One. 2022;17:e0271681. https:\/\/doi.org\/10.1371\/journal.pone.0271681.","journal-title":"PLoS One"},{"key":"494_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JND-230159","volume":"11","author":"G Stimpson","year":"2024","unstructured":"Stimpson G, Ridout D, Wolfe A, Milev E, O\u2019Reilly E, Manzur A, et al. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10\u200am Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys. J Neuromuscul Dis. 2024;11:153\u201366.","journal-title":"J Neuromuscul Dis"},{"key":"494_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3233\/JND-210743","volume":"9","author":"L Servais","year":"2022","unstructured":"Servais L, Yen K, Guridi M, Lukawy J, Vissi\u00e8re D, Strijbos P. Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials. J Neuromuscul Dis. 2022;9:335\u201346.","journal-title":"J Neuromuscul Dis"},{"key":"494_CR10","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A, Wong B, Keeler A, Blackwood M, Ma K, Huang S, et al. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy. N Engl J Med. 2023;389:1203\u201310. https:\/\/doi.org\/10.1056\/NEJMoa2307798.","journal-title":"N Engl J Med"},{"key":"494_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00108-024-01711-5","volume":"65","author":"S Horn","year":"2024","unstructured":"Horn S, Fehse B. Wie sicher ist die Gentherapie? : Zweiter Todesfall nach Therapie der Duchenne-Muskeldystrophie [How safe is gene therapy? : Second death after Duchenne therapy]. Inn Med. 2024;65:617\u201323. https:\/\/doi.org\/10.1007\/s00108-024-01711-5.","journal-title":"Inn Med"},{"key":"494_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209206","volume":"102","author":"M Schiava","year":"2024","unstructured":"Schiava M, McDermott MP, Broomfield J, Abrams KR, Mayhew AG, McDonald CM, et al. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial. Neurology. 2024;102:e209206. https:\/\/doi.org\/10.1212\/WNL.0000000000209206.","journal-title":"Neurology"},{"key":"494_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JND-221527","volume":"10","author":"Y Fang","year":"2023","unstructured":"Fang Y, McDonald CM, Clemens PR, Gordish HD, Illei K, Hoffman EP, et al. Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2023;10:349\u201364. https:\/\/doi.org\/10.3233\/JND-221527.","journal-title":"J Neuromuscul Dis"},{"key":"494_CR14","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","volume":"24","author":"C Godfrey","year":"2015","unstructured":"Godfrey C, Muses S, McClorey G, Wells KE, Coursindel T, Terry RL, et al. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol Genet. 2015;24:4225\u201337. https:\/\/doi.org\/10.1093\/hmg\/ddv155.","journal-title":"Hum Mol Genet"},{"key":"494_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ana.25951","volume":"89","author":"Y de Feraudy","year":"2021","unstructured":"de Feraudy Y, Ben Yaou R, Wahbi K, Stalens C, Stantzou A, Laugel V, et al. Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy. Ann Neurol. 2021;89:280\u201392. https:\/\/doi.org\/10.1002\/ana.25951.","journal-title":"Ann Neurol"},{"key":"494_CR16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.nmd.2007.07.005","volume":"17","author":"M Neri","year":"2007","unstructured":"Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord. 2007;17:913\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2007.07.005.","journal-title":"Neuromuscul Disord"},{"key":"494_CR17","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.050395","volume":"16","author":"DO Riddell","year":"2023","unstructured":"Riddell DO, Hildyard JCW, Harron RCM, Taylor-Brown F, Kornegay JN, Wells DJ, et al. Longitudinal assessment of skeletal muscle functional mechanics in the DE50-MD dog model of Duchenne muscular dystrophy. Dis Model Mech. 2023;16:dmm050395. https:\/\/doi.org\/10.1242\/dmm.050395.","journal-title":"Dis Model Mech"},{"key":"494_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-023-00334-y","volume":"14","author":"JF Boehler","year":"2024","unstructured":"Boehler JF, Brown KJ, Ricotti V, Morris CA. N-terminal titin fragment: a non-invasive, pharmacodynamic biomarker for microdystrophin efficacy. Skelet Muscle. 2024;14:2.","journal-title":"Skelet Muscle"},{"key":"494_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1474-4422(24)00257-6","volume":"23","author":"E Mercuri","year":"2024","unstructured":"Mercuri E, Vilchez JJ, Boespflug-Tanguy O, Zaidman CM, Mah JK, Goemans N, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23:393\u2013403. https:\/\/doi.org\/10.1016\/S1474-4422(24)00257-6.","journal-title":"Lancet Neurol"},{"key":"494_CR20","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1001\/jama.2024.5613","volume":"331","author":"DM Rind","year":"2024","unstructured":"Rind DM. The FDA and Gene Therapy for Duchenne Muscular Dystrophy. JAMA. 2024;331:1705\u20136. https:\/\/doi.org\/10.1001\/jama.2024.5613.","journal-title":"JAMA"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00494-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:05:56Z","timestamp":1732068356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00494-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":20,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00494-6","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FM has received grants from Sarepta, Wave Therapeutics, and PTC, and personal fees from Avexis, Roche, Pfizer, Dyne Therapeutics, and Sarepta (outside the submitted work). GB is principal investigator of clinical trials by Pfizer, NS Pharma, and Reveragen, and has received speaker and\/or consulting fees from Sarepta, Pfizer, PTC Therapeutics, Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche (outside the submitted work), and grants to UCL from Sarepta, Pfizer, Roche, Novartis and Biogen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}